Rifamycin Shows No Major Shift in Gut Resistance

A small randomized trial in cirrhosis patients found the antibiotic did not significantly change gut antibiotic resistance gene levels.

Updated on Nov. 10, 2026 in Life Sciences

Rifamycin Shows No Major Shift in Gut Resistance

Researchers tested rifamycin against placebo in 30 outpatients with cirrhosis over 30 days and found no significant change in gut antibiotic resistance gene levels after statistical correction. The antibiotic was associated with improved sarcopenia and was found to be safe in the study.

Why it matters

Antibiotic resistance is a growing concern for clinicians managing cirrhosis, and rifaximin has previously been implicated in the emergence of resistance genes, particularly for vancomycin. The findings offer an early, limited signal that rifamycin may not drive that resistance in the short term.

The evidence comes from a small randomized trial of 30 patients (15 per arm) using metagenomic sequencing of stool samples at baseline and end of treatment. Exploratory analyses showed lower vancomycin, tetracycline and nitroimidazole resistance gene levels after rifamycin than at baseline, but these were not significant after statistical correction, and effects on longer-term resistance remain unknown.

The players

Jasmohan S Bajaj

Lead researcher on the trial and a hepatologist at Virginia Commonwealth University in Richmond, Virginia, who studies complications of cirrhosis.

The details

Participants with cirrhosis and minimal hepatic encephalopathy were randomly assigned to rifamycin 600 mg twice daily or placebo for 30 days, with stool analyzed using the Comprehensive Antibiotic Resistance Database. Vancomycin and tetracycline resistance gene levels rose in the placebo group, no infections were reported in the rifamycin group, and cognition and Model for End-Stage Liver Disease scores were stable in both arms.

Timeline

  1. 30 days: duration of rifamycin or placebo treatment in the trial

  2. 2026: findings presented at The Liver Meeting in Denver, Colorado

Health Landscape

The study tests whether rifamycin, a related antibiotic, avoids the vancomycin resistance pattern previously linked to rifaximin in cirrhosis care. Its short 30-day, 30-patient design means it extends rather than settles the ongoing question of how these antibiotics affect gut microbial resistance over time.

For people living with cirrhosis, the trial suggests rifamycin is generally tolerated in the short term without signs of new infections. Patients and clinicians should still weigh these early findings against the limited size and duration of the study before any change in treatment.

The takeaway

Small early trials can flag promising safety and resistance signals, but larger and longer studies are needed before rifamycin's effect on gut resistance is settled. Clinicians tracking cirrhosis care should watch for follow-up research on these findings.

Further reading

For related context on how microbes and drugs interact in the body, explore more in Life Sciences.